These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy. Sasaki M; Sato Y Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196 [TBL] [Abstract][Full Text] [Related]
5. Analysis of p53 expression in precancerous and malignant gastric mucosa. Romiti A; Moretti A; Vecchione A; Muraro R; Feudi ML; Rinaldi V; Mancini R; Valli C; Mozzicafreddo A; Frati L; Tomao S Oncol Rep; 1998; 5(1):109-13. PubMed ID: 9458303 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors. Sasaki M; Sato Y Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541 [TBL] [Abstract][Full Text] [Related]
7. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Riener MO; Fritzsche FR; Clavien PA; Pestalozzi BC; Probst-Hensch N; Jochum W; Kristiansen G Hum Pathol; 2009 Oct; 40(10):1377-83. PubMed ID: 19467694 [TBL] [Abstract][Full Text] [Related]
8. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Wang L; Li HG; Xia ZS; Lü J; Peng TS Chin Med J (Engl); 2010 Dec; 123(24):3554-8. PubMed ID: 22166630 [TBL] [Abstract][Full Text] [Related]
9. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Li L; Xu H; Spaulding BO; Cheng L; Simon R; Yao JL; di Sant'Agnese PA; Bourne PA; Huang J Hum Pathol; 2008 Aug; 39(8):1205-11. PubMed ID: 18547613 [TBL] [Abstract][Full Text] [Related]
10. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334 [TBL] [Abstract][Full Text] [Related]
11. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. Joypaul BV; Newman EL; Hopwood D; Grant A; Qureshi S; Lane DP; Cuschieri A J Pathol; 1993 Jul; 170(3):279-83. PubMed ID: 8133401 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast. Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988 [TBL] [Abstract][Full Text] [Related]
13. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408 [TBL] [Abstract][Full Text] [Related]
14. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Ishida M; Gomyo Y; Tatebe S; Ohfuji S; Ito H Virchows Arch; 1996 Jul; 428(4-5):229-35. PubMed ID: 8764931 [TBL] [Abstract][Full Text] [Related]
15. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression. Ito E; Saito K; Takizawa T; Koike M J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm. Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases. Senoo J; Mikata R; Kishimoto T; Hayashi M; Kusakabe Y; Yasui S; Yamato M; Ohyama H; Sugiyama H; Tsuyuguchi T; Yoshitomi H; Ohtsuka M; Maeda J; Ota S; Nakatani Y; Kato N Pancreatology; 2018 Mar; 18(2):176-183. PubMed ID: 29305088 [TBL] [Abstract][Full Text] [Related]
18. p53 alteration in gastric precancerous lesions. Shiao YH; Rugge M; Correa P; Lehmann HP; Scheer WD Am J Pathol; 1994 Mar; 144(3):511-7. PubMed ID: 8129036 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of p53 in gastric carcinoma. Fukunaga M; Monden T; Nakanishi H; Ohue M; Fukuda K; Tomita N; Shimano T; Mori T Am J Clin Pathol; 1994 Feb; 101(2):177-80. PubMed ID: 8116572 [TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa. Fogt F; Nikulasson ST; Holden JA; Alder SA; Hallgrimsson J; Jessup MJ; O'Brien MJ; Lavin PT; Goldman H Mod Pathol; 1997 Apr; 10(4):296-302. PubMed ID: 9110290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]